CN113862181A - Bifidobacterium lactis RK-7782 with intestinal tract regulating function and application thereof - Google Patents
Bifidobacterium lactis RK-7782 with intestinal tract regulating function and application thereof Download PDFInfo
- Publication number
- CN113862181A CN113862181A CN202111101700.6A CN202111101700A CN113862181A CN 113862181 A CN113862181 A CN 113862181A CN 202111101700 A CN202111101700 A CN 202111101700A CN 113862181 A CN113862181 A CN 113862181A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium lactis
- bifidobacterium
- intestinal
- lactis
- anaerobic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 71
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 71
- 210000001035 gastrointestinal tract Anatomy 0.000 title description 9
- 230000001105 regulatory effect Effects 0.000 title description 6
- 230000000968 intestinal effect Effects 0.000 claims abstract description 33
- 235000013618 yogurt Nutrition 0.000 claims abstract description 30
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 20
- 239000006041 probiotic Substances 0.000 claims abstract description 17
- 235000018291 probiotics Nutrition 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 15
- 210000004051 gastric juice Anatomy 0.000 claims abstract description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000013351 cheese Nutrition 0.000 claims abstract description 7
- 230000000529 probiotic effect Effects 0.000 claims abstract description 7
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 5
- 239000004310 lactic acid Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 239000001963 growth medium Substances 0.000 claims description 14
- 210000003608 fece Anatomy 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 238000003794 Gram staining Methods 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 3
- 238000009395 breeding Methods 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 230000001788 irregular Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 244000052616 bacterial pathogen Species 0.000 abstract description 9
- 210000002249 digestive system Anatomy 0.000 abstract description 6
- 230000007123 defense Effects 0.000 abstract description 3
- 241000588724 Escherichia coli Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 10
- 230000003385 bacteriostatic effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000013872 defecation Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000007413 intestinal health Effects 0.000 description 7
- 230000035622 drinking Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000002416 diarrheagenic effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 241000607768 Shigella Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000607598 Vibrio Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 4
- 230000000369 enteropathogenic effect Effects 0.000 description 4
- 230000000688 enterotoxigenic effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010079723 Shiga Toxin Proteins 0.000 description 3
- 241000607766 Shigella boydii Species 0.000 description 3
- 241000607764 Shigella dysenteriae Species 0.000 description 3
- 241000607762 Shigella flexneri Species 0.000 description 3
- 241000607760 Shigella sonnei Species 0.000 description 3
- 241000194020 Streptococcus thermophilus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229940007046 shigella dysenteriae Drugs 0.000 description 3
- 229940115939 shigella sonnei Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000000035 biogenic effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
- A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a Bifidobacterium lactis, which belongs to Bifidobacterium (Bifidobacterium) and is preserved in the common microorganism center of China general microbiological culture Collection center at 24/8 in 2021, wherein the address is as follows: no. 3 of Xilu No. 1 of Beijing, Chaoyang, the institute for microbiology of Chinese academy of sciences, is classified and named as Bifidobacterium lactis RK-7782 (deposited number CGMCC No. 23181). The bifidobacterium lactis has strong gastric juice and intestinal juice tolerance, has obvious inhibition capacity on intestinal pathogenic bacteria, is proved to have safety, can be used for preparing yoghourt, cheese, probiotic compound, instant lactic acid bacteria and the like, can obviously improve the microenvironment of intestinal flora of a human body, and enhances the defense capacity of a digestive system of the human body.
Description
Technical Field
The invention relates to the technical field of biological strains, in particular to a bifidobacterium lactis RK-7782 with an intestinal regulation function and application thereof.
Background
Probiotics are a class of active microorganisms that can improve the microbial ecological balance of the host and exert beneficial effects on the human body. In a normal adult, the intestinal tract contains more than 1000 species of microorganisms, which can be divided into three main groups: the original flora, the conditional pathogenic bacteria and the road bacteria. The original flora is intestinal dominant bacteria with the functions of immunoregulation and the like; the conditional pathogenic bacteria are harmless when intestinal flora is balanced, and can be harmful to human bodies under specific conditions; harmful bacteria, which are normally small in number, can cause diseases when the flora is unbalanced. People with constipation and diarrhea are often accompanied by an imbalance of the intestinal flora.
Nowadays, people generally live busy, and factors such as difficulty in regularity of daily work and rest easily cause the abnormality of the intestinal health of people at present, such as constipation and diarrhea, and become sub-health manifestations which are common and more important for people of all ages. Intestinal abnormalities can be treated by drugs, but the micro-ecological balance of the intestinal tract is affected, and the drug taking is not a healthy way for most people, and drug dependence is easy to form. The active probiotics with the intestinal optimization function or the yoghourt product carrying the active probiotics can improve the intestinal environment of a human body and relieve or eliminate constipation and diarrhea, not only can not damage the intestinal microenvironment of the human body, but also has the recovery and improvement effects, and is a better choice for adjusting and optimizing the intestinal health of the human body. Bifidobacterium lactis is a common intestinal probiotic. Many foods contain probiotics, but they do not work when eaten, and several conditions need to be met for the probiotics to work: firstly, the medicine can live to reach the intestines, secondly, a certain amount of the medicine can be reached, and thirdly, the medicine can exert obvious effects.
However, the known probiotics have poor resistance to the strong acid digestive juice of gastric juice and intestinal juice and are easy to be killed when the probiotics pass through the stomach and intestine, so that after the product containing the probiotics in the edible yoghurt is eaten, living bacteria which can really have the effects of regulating and balancing the digestive system of a human body are very few, and the edible probiotics yoghurt has no effect or poor effect. Therefore, probiotics with stronger gastric juice and intestinal juice resistance needs to be further screened out to ensure that a large amount of probiotics can survive after oral administration or eating, and play a role in regulating the digestive system of a human body.
Disclosure of Invention
Technical problem to be solved
In view of the above-mentioned drawbacks and deficiencies of the prior art, the present invention provides a bifidobacterium lactis strain RK-7782 with intestinal tract regulating function and its use, which has been shown to have higher resistance to artificial gastric juice and artificial intestinal juice, thus ensuring survival of a large amount after gastrointestinal digestion and reproduction in the digestive system of the body to exert the probiotic effect.
(II) technical scheme
In order to achieve the purpose, the invention adopts the main technical scheme that:
in a first aspect, the present invention provides a Bifidobacterium lactis belonging to the genus Bifidobacterium (Bifidobacterium), which has been deposited at 24/8/2021 in the general microbiological center of the china committee for culture collection of microorganisms at the address: no. 3 of Xilu No. 1 of Beijing, Chaoyang, the institute for microbiology of Chinese academy of sciences, is classified and named as Bifidobacterium lactis RK-7782 (deposited number CGMCC No. 23181).
Bifidobacterium lactis RK-7782(Bifidobacterium lactis) is isolated from intestinal tract of healthy infant, specifically from feces of pure breast-fed healthy infant, and is obtained by separating and screening, and purifying by selective culture method to obtain Bifidobacterium lactis RK-7782(Bifidobacterium lactis) strain.
The Bifidobacterium lactis RK-7782(Bifidobacterium lactis) strain is proved to have very high characteristics of resisting artificial gastric juice and artificial intestinal juice and can survive in a large amount after digestion of stomach and intestine, so that the Bifidobacterium lactis RK-7782 can be easily ingested by eaters when being prepared into probiotic compounds or added into dairy products such as yoghourt, cheese and the like, and can survive and reproduce in the intestinal tracts of the eaters to play a role in regulating the intestinal tracts.
The breeding method of the bifidobacterium lactis comprises the following steps:
(1) fully stirring and scattering a healthy infant feces sample soaked in the anaerobic diluent to obtain feces suspension, continuously diluting the feces suspension by 10 times of gradient of the anaerobic diluent, pouring a flat plate by using an NPNL-X-Gal selective culture medium, culturing for 40-60 hours at 37-37.5 ℃ in an anaerobic bag in cooperation with an anaerobic gas production bag, and separating potential bifidobacteria;
(2) selecting blue colonies from the plate, performing gram-staining microscopic examination, selecting gram-positive colonies with irregular bacillus thalli, and continuously separating and purifying for 2-3 times until a pure culture of potential bifidobacterium is separated;
(3) culturing the above separated pure culture of Bifidobacterium respectively in artificial gastric juice and artificial intestinal juice for 4-6 hr to select strains with good tolerance;
(4) and (3) performing strain identification on the screened Bifidobacterium pure culture to obtain Bifidobacterium lactis RK-7782(Bifidobacterium lactis).
In a second aspect, the present invention provides the use of bifidobacterium lactis in the preparation of yoghurt products, cheese, buttermilk, solid beverages, ready-to-eat lactic acid bacteria and the like.
Compared with the prior art, the invention has the following beneficial effects:
(1) the bifidobacterium lactis strain bred by the invention has excellent capability of resisting human gastric juice and intestinal juice, and the number of the strain is increased or only slightly reduced even after 4 hours of immersion of the artificial gastric juice and the artificial intestinal juice (without other culture media).
(2) The compound has obvious inhibition capability on intestinal pathogenic bacteria, and particularly has good inhibition effect on 'diarrheagenic escherichia coli', and the escherichia coli comprises the following six types: intestinal accumulating Escherichia coli (EAEC); enterotoxigenic escherichia coli (ETEC); shiga toxin-producing escherichia coli (STEC); enteropathogenic escherichia coli (EPEC); enterohemorrhagic escherichia coli (EHEC); intestinal invasive Escherichia coli (EIEC).
(3) The bifidobacterium lactis strain bred by the method has the bacteriostatic effect on shigella, salmonella enteritidis and staphylococcus aureus; the shigella comprises the following four bacteria: shigella boydii, Shigella flexneri, Shigella sonnei and Shigella dysenteriae.
(4) In addition, the bifidobacterium lactis strain bred by the invention has the bacteriostatic effect on pseudomonas aeruginosa and vibrio desulfurated.
The bifidobacterium lactis strain bred by the method also has potential function of improving immunity and improving the intestinal health of people, and is particularly characterized in that the problems of seasonal enteritis, diet or drinking water unclean enteritis and the like are prevented by improving the microenvironment of intestinal flora of a human body and enhancing the defense capacity of a digestive system of the human body.
Drawings
FIG. 1 shows the tolerance of Bifidobacterium lactis RK-7782 in gastric juice.
FIG. 2 shows the tolerance of Bifidobacterium lactis RK-7782 in 0.3% bile solution of gastric juice.
FIG. 3 shows the bacteriostatic effect of Bifidobacterium lactis RK-7782 on diarrheagenic Escherichia coli.
FIG. 4 shows the bacteriostatic effect of Bifidobacterium lactis RK-7782 on Shigella, Salmonella enteritidis and Staphylococcus aureus.
FIG. 5 shows the bacteriostatic effect of Bifidobacterium lactis RK-7782 on Pseudomonas aeruginosa and Vibrio desulphuricus.
Detailed Description
For the purpose of better explaining the present invention and to facilitate understanding, the present invention will be described in detail by way of specific embodiments with reference to the accompanying drawings.
The invention aims to provide bifidobacterium lactis RK-7782, which not only can improve the intestinal health condition of people, but also has the potential function of improving immunity; the intestinal health of people is improved, and the intestinal health of people is specifically characterized in that the intestinal flora microenvironment of human bodies is improved, the defense capability of the digestive system of human bodies is enhanced, and the problems of seasonal enteritis, food or drinking water unclean enteritis and the like are prevented. Meanwhile, the invention provides a simple and easy breeding method and application, and the method has high efficiency and low cost.
The Bifidobacterium lactis RK-7782 is Bifidobacterium lactis RK-7782 in Bifidobacterium (Bifidobacterium), and the Bifidobacterium lactis RK-7782 is preserved in the China general microbiological culture Collection center at 24/8 of 2021, with the address: no. 3 of Xilu No. 1 of Beijing, Chaoyang, the institute for microbiology of Chinese academy of sciences, is classified and named as Bifidobacterium lactis RK-7782 (deposited number CGMCC No. 23181).
The bifidobacterium lactis RK-7782 strain is prepared by researching the feces of healthy infants in the lactation period, selecting all infant feces samples with normal physical condition indexes, good sleep, good spirit, good absorption, weight and length indexes all on the middle-high infant of the same age, and separating and purifying by using a selective culture method. The bifidobacterium lactis RK-7782 is prepared into a biological microbial inoculum for preparing and producing yoghourt, cheese, solid beverage, instant lactic acid bacteria and the like to improve the intestinal health condition of people.
The present invention is further illustrated by the following examples, which are not intended to limit the practice of the invention.
Example 1
1. Collecting samples: beginning at infant care institute in city in 12 months 2019, the health status of infants in the area was anonymously investigated and samples of infant feces from infants between 3 and 8 months were collected.
And (4) soaking the fecal sample in an anaerobic diluent, numbering, and storing in liquid nitrogen. After a predetermined number of samples were collected, all samples were transferred to a dry ice incubator, stored at-80 ℃ and subjected to strain isolation culture within 7 days.
2. Separation and screening method
(1) Fully stirring and scattering a healthy infant feces sample soaked in the anaerobic diluent to obtain a feces suspension, continuously diluting the feces suspension by 10 times of gradient of the anaerobic diluent, pouring a flat plate by using an NPNL-X-Gal selective culture medium, culturing for 40-60h at 37 ℃ in an anaerobic bag in cooperation with an anaerobic gas production bag, and separating potential bifidobacteria;
(2) selecting blue colonies from the plate, performing gram-staining microscopic examination, selecting gram-positive colonies with irregular bacillus thalli, and continuously separating and purifying for 2-3 times until a pure culture of potential bifidobacterium is separated;
(3) culturing the separated bifidobacterium pure cultures in artificial gastric juice and artificial intestinal juice for 5h respectively to select strains with excellent tolerance;
(4) and (3) performing strain identification on the screened Bifidobacterium pure culture to obtain Bifidobacterium lactis RK-7782(Bifidobacterium lactis).
(3) And (4) preservation: the strain is delivered to China general microbiological culture Collection center (CGMCC) for preservation, and the preservation number is CGMCC No. 23181.
(4) Evaluation of safety of Strain
Safety evaluation is a prerequisite for probiotic application, and Bifidobacterium lactis is a widely researched potential probiotic strain. The invention evaluates the safety of the strain in vitro and in vivo and provides basic guarantee for the application of the strain.
Antibiotic resistance to sensitivity and biogenic amine production were evaluated by in vitro experiments; oral toxicity and translocation risk were assessed in vivo.
The result shows that the bifidobacterium lactis RK-7782 has no antibiotic sensitivity peculiar to the strain, and the risk of antibiotic resistance transverse transfer is eliminated; no bacterial strain is found to produce biogenic amine by culturing in a decarboxylase culture medium; the gavage test shows that 108、109、1010After the cfu/mouse is fed for 21 days, the mouse has no adverse reaction, and the strain is not found in blood, kidney and liver. The study did not find unsafe factors for the strains.
Example 2
The following is a detailed description of animal experiments and bacterial translocation experiments.
1. Experimental materials: bifidobacterium lactis strain (Bifidobacterium lactis RK-7782)
2. Experimental methods
(1) Animal experiment design:
SPF grade Balb/C mice, 6 to 8 weeks old, female. Feeding in SPF-grade animal houses: temperature 25 + -2 deg.C, humidity 45% + -1%, 12h light/dark cycle, free drinking and food intake. The mice were randomly divided into 10 groups (10 per group) as follows:
gavage group (3 groups), 2X 10 for each mouse per day8，2×109And 2X 1010cfu/mouse gavage for 30d (0.2 mL per mouse per day);
for the control group, the stomach was perfused with physiological saline;
mice were observed daily for general signs of appearance, behavior, toxic manifestations and mortality during the experiment, and mice were recorded weekly for weight, food intake.
(2) Statistical analysis the test results data are expressed as mean ± standard deviation (± SD). The mean value comparison among different treatment methods adopts single-factor analysis of variance to carry out the difference significance test, and the displacement rate comparison among different treatments adopts the chi-square test. All statistical analyses were performed using statistical software SPSS version 17.0 with significance levels P < 0.05.
(3) Analysis of results
The blood routine index reflects the side effect of the experimental strain in blood, and the blood biochemical index reflects the conditions of nutrient deficiency and metabolic imbalance. These indicators typically change earlier than other clinical symptoms.
Table 1: general index of blood group by oral gavage (n as 10)
The blood routine and blood biochemical indexes of the experimental group and the control group in the experiment are not changed obviously, which shows that the experimental strain has no adverse effect on experimental animals and has higher translocation safety. Safety evaluation of the bifidobacterium lactis RK-7782 shows no unsafe factors of the strain.
Example 3
And (3) evaluating strain tolerance:
tolerance was assessed by comparing the strain Bifidobacterium lactis RK-7782 with that of commercial Bifidobacterium lactis CP-9. The resistance of CP-9 was evaluated by plate counting using acid resistance, bile salt resistance, and simulated artificial gastrointestinal fluid.
The following conclusions can be drawn from the experimental results, which are shown in FIGS. 1-2.
The survival number of Bifidobacterium lactis RK-7782 increased by about 0.5 orders of magnitude at pH3 and decreased by about two orders of magnitude in 0.3% bile salts over 0-4 h. Furthermore, the survival number of Bifidobacterium lactis RK-7782 decreased only by about 0.5 orders of magnitude within 4h in low concentrations (mass concentration) of 0.1% bile salts.
The experiments prove that the strain is equivalent to or even better than the Bifidobacterium lactis CP-9 in acid resistance, cholate resistance and artificial gastrointestinal fluid resistance, and has the potential of developing into a commercial strain.
Example 4
Evaluation of the inhibition capacity of the bifidobacterium lactis RK-7782 strain on intestinal pathogenic bacteria:
1. bacteriostatic effect on diarrheagenic escherichia coli
The diarrheagenic escherichia coli includes the following six species: intestinal accumulating Escherichia coli (EAEC); enterotoxigenic escherichia coli (ETEC); shiga toxin-producing escherichia coli (STEC); enteropathogenic escherichia coli (EPEC); enterohemorrhagic escherichia coli (EHEC); intestinal invasive Escherichia coli (EIEC).
Test protocol: comparing the diameters of the inhibition zones by an Oxford cup method, wherein the specific test method comprises the following steps:
(1) preparing a solid culture medium: weighing 2g of tryptone, 1g of yeast extract and 2g of NaCl respectively; adding the weighed medicine into a large conical flask, adding 150mL of deionized water, and shaking to completely dissolve the medicine; weighing 3g of agar powder, adding water to 200mL of the solution, and placing the solution in a water bath kettle to be heated and dissolved at 90 ℃: after the fat powder is completely dissolved, the culture medium is sterilized in a high-pressure steam sterilizer at 121 ℃ for 30 min. The experimental bacterium was diarrheagenic escherichia coli.
(2) The bacteriostatic test only adopts the Oxford cup method. The method comprises the following specific steps:
cooling a culture medium containing 2.0% of agar to about 50 ℃, pouring 10mL of the culture medium into a sterile plate, and airing the culture medium in a clean workbench;
secondly, placing the sterilized oxford cup in a dish with the agar, and standing for 10 min;
③ adding 1mL of pathogenic bacteria cultured overnight into 100mL of culture medium cooled to 50 ℃ and fully mixing;
pouring 10mL of the culture medium on a flat plate with the Oxford cup, and clamping the Oxford cup out after solidification to form an Oxford cup hole;
fifthly, 0.1mL of overnight cultured bifidobacterium lactis RK-7782 fermentation liquid is injected into each Oxford cup hole, and the mixture is kept stand at 37 ℃ for anaerobic culture for 48 to 72 hours. And a 0.9% sodium chloride solution was used as a negative control.
The experimental results are shown in fig. 3, the left side of each plate is blank control, the right side is inhibition zone, and the inhibition diameter is as follows by statistics: TABLE 2
| Intestinal pathogenic bacteria | Diameter of antibacterial ring (unit: millimeter) |
| Intestinal accumulating Escherichia coli (EAEC) | 14.22 |
| Enterotoxigenic large intestine ehich (ETEC) | 15.70 |
| Shiga toxin producing Escherichia coli (STEC) | 14.80 |
| Enteropathogenic Escherichia coli (EPEC) | 13.88 |
| Enterohemorrhagic Escherichia coli (EHEC) | 14.26 |
| Enterotoxigenic large intestine ehich (EIEC) | 16.58 |
2. Bacteriostatic effect on Shigella, Salmonella enteritidis and Staphylococcus aureus
According to the Oxford cup method test method, the experimental bacteria in the solid culture medium are changed into the following six bacteria: s Shigella boydii; shigella flexneri; shigella sonnei; shigella dysenteriae, Salmonella enteritidis and Staphylococcus aureus. The remainder being as described above.
The experimental results are shown in fig. 4, the left side of each plate is blank control, the right side is inhibition zone, and the inhibition diameter is as follows by statistics: TABLE 3
| Intestinal pathogenic bacteria | Diameter of antibacterial ring (unit: millimeter) |
| Shigella boydii | 18.54 |
| Shigella flexneri | 18.20 |
| Shigella sonnei | 16.80 |
| Shigella dysenteriae | 15.40 |
| Salmonella enteritidis | 15.44 |
| Staphylococcus aureus | 13.28 |
3. Bacteriostatic effect on pseudomonas aeruginosa and vibrio desulfurated
According to the Oxford cup method test method, the experimental bacteria in the solid culture medium are changed into the following two types: pseudomonas aeruginosa and vibrio desulfurizate. The remainder being as described above.
The experimental results are shown in fig. 5, the left side of each plate is blank control, the right side is inhibition zone, and the inhibition diameter is as follows by statistics: TABLE 4
| Intestinal pathogenic bacteria | Diameter of antibacterial ring (unit: millimeter) |
| Pyocutaneous disease | 17.60 |
| Desulfurization of | 11.44 |
The results of the example show that the bifidobacterium lactis RK-7782 strain screened by the invention has good inhibitory effect on enteropathogenic bacteria.
Example 5
The yogurt containing bifidobacterium lactis RK-7782 has the effect of improving the intestinal tracts of healthy adults: 1. experimental procedure
The experiment is divided into the following three stages:
(1) primary screening by volunteers:
and screening volunteers meeting the experimental requirements.
(2) And (3) emptying period:
the emptying period lasted for 7 days. During the period, the volunteers could not drink any fermented product (including yogurt, cheese, active lactic acid bacteria beverage, etc.), but could drink milk. Day 8 is the time of first stool sample collection.
(3) And (3) yogurt drinking period:
the drinking period lasts 15 days. Meanwhile, the volunteers cannot drink any fermented product (including yogurt, cheese, active lactobacillus beverage, etc.) except for drinking a bottle of yogurt within one hour after lunch every day. In addition, diet statistics need to be filled out on time each day. The second fecal sample collection time is taken on day 8 of drinking, the third fecal sample collection time is taken on day 15 of drinking, and the body weight is recorded.
The preparation method of the yoghourt containing the bifidobacterium lactis comprises the following steps: heating raw milk to 80 deg.C, adding mixed white sugar, agar, concentrated lactalbumin, and starch, homogenizing, sterilizing, and cooling to 40 deg.C. Inoculating Streptococcus thermophilus, Lactobacillus delbrueckii subsp bulgaricus and Bifidobacterium lactis RK-7782, stirring, mixing, standing at 37-40 deg.C, and fermenting until the titer acidity is greater than 70 ° T to obtain yogurt. Demulsifying the yoghourt, cooling to 2-4 ℃, filling, transferring into an environment with the temperature of 2-4 ℃ for refrigeration and after-ripening for 8h, and obtaining the yoghourt rich in bifidobacterium lactis.
2. Experimental samples and population grouping
Through screening, 90 people are grouped, and the grouping condition of the crowd is shown in the following table:
TABLE 5
| Group of | For male | Woman | Total number of people | Mean age |
| Supermarket yoghurt control group | 20 | 25 | 45 | 25.5±1.3 |
| Yogurt group containing Bifidobacterium lactis | 20 | 25 | 45 | 26.±4.5 |
Experimental samples:
(1) supermarket yoghourt: set yoghurt, 200 g/bottle, fermentation strain: streptococcus thermophilus and lactobacillus bulgaricus.
(2) Yogurt group containing bifidobacterium lactis: set yoghurt, 200 g/bottle, fermentation strain: streptococcus thermophilus, Lactobacillus bulgaricus, Bifidobacterium lactis RK-7782 (maintained at 1 × 10 during the experiment period)8Above CFU/ml).
3. Defecation status scoring standard (Table 6)
4. The experimental results are as follows: statistics of defecation times (Table 7)
The defecation frequency of people taking the common yoghourt is increased by 0.06 times per day, and the defecation frequency of 10.5 percent of people is improved. And the defecation frequency of the crowd taking the yoghourt containing the bifidobacterium lactis RK-7782 is increased by 0.41 times per day, and the defecation frequency of 36.6 percent of the crowd is improved, compared with that of a control group, the difference is obvious, which shows that the defecation frequency is obviously improved by taking the yoghourt containing the bifidobacterium lactis.
In addition, the proportion of persons who improved the stool shape was 20.8% for the persons who drunk yogurt from the general market and 45.9% for the persons who drunk yogurt containing bifidobacterium lactis RK-7782, compared according to the bristol stool scoring method (statistical analysis p < 0.05).
The bristol stool score is an important index for evaluating the stool health. The result shows that compared with the common yoghourt, the yoghourt containing the bifidobacterium lactis RK-7782 can obviously improve the excrement form of people.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (3)
1. A Bifidobacterium lactis belonging to the genus Bifidobacterium (Bifidobacterium) and having been deposited at 24/8/2021 in the China general microbiological culture Collection center (CGMCC), address: no. 3 of Xilu No. 1 of Beijing, Chaoyang, the institute for microbiology of Chinese academy of sciences, is classified and named as Bifidobacterium lactis RK-7782 (deposited number CGMCC No. 23181).
2. The bifidobacterium lactis as claimed in claim 1, wherein the breeding method comprises the following steps:
(1) fully stirring and scattering a healthy infant feces sample soaked in the anaerobic diluent to obtain feces suspension, continuously diluting the feces suspension by 10 times of gradient of the anaerobic diluent, pouring a flat plate by using an NPNL-X-Gal selective culture medium, culturing for 40-60 hours at 37-37.5 ℃ in an anaerobic bag in cooperation with an anaerobic gas production bag, and separating potential bifidobacteria;
(2) selecting blue colonies from the plate, performing gram-staining microscopic examination, selecting gram-positive colonies with irregular bacillus thalli, and continuously separating and purifying for 2-3 times until a pure culture of potential bifidobacterium is separated;
(3) culturing the above separated pure culture of Bifidobacterium respectively in artificial gastric juice and artificial intestinal juice for 4-6 hr to select strains with good tolerance;
(4) and (3) performing strain identification on the screened Bifidobacterium pure culture to obtain Bifidobacterium lactis RK-7782(Bifidobacterium lactis).
3. Application of Bifidobacterium lactis is provided, wherein the Bifidobacterium lactis is classified and named as Bifidobacterium lactis RK-7782 with a preservation number of CGMCC No. 23181; the preparation method is applied to preparing yoghourt, cheese, probiotic compound or instant lactic acid bacteria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111101700.6A CN113862181A (en) | 2021-09-18 | 2021-09-18 | Bifidobacterium lactis RK-7782 with intestinal tract regulating function and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111101700.6A CN113862181A (en) | 2021-09-18 | 2021-09-18 | Bifidobacterium lactis RK-7782 with intestinal tract regulating function and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113862181A true CN113862181A (en) | 2021-12-31 |
Family
ID=78992913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111101700.6A Pending CN113862181A (en) | 2021-09-18 | 2021-09-18 | Bifidobacterium lactis RK-7782 with intestinal tract regulating function and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113862181A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115747121A (en) * | 2022-12-12 | 2023-03-07 | 威凯海思(山东)生物工程有限公司 | Bifidobacterium lactis HSLA-009, microbial inoculum and preparation method and application thereof |
| CN116445356A (en) * | 2023-04-28 | 2023-07-18 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107893044A (en) * | 2017-12-27 | 2018-04-10 | 江南大学 | One plant of bifidobacterium longum and its application |
| CN110577919A (en) * | 2019-10-14 | 2019-12-17 | 汉臣氏（沈阳）儿童制品有限公司 | heat-resistant bifidobacterium animalis subsp lactis separated from infant feces |
| CN110959676A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Fermented milk product containing bifidobacterium lactis and application thereof |
| CN110964655A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Bifidobacterium lactis BL-99 capable of regulating gastrointestinal flora and application thereof |
| CN110964657A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Bifidobacterium lactis BL-99 capable of improving immunity and application thereof |
| CN112175864A (en) * | 2020-09-18 | 2021-01-05 | 山东得益乳业股份有限公司 | Bifidobacterium animalis and breeding method and application thereof |
| CN113088465A (en) * | 2021-04-02 | 2021-07-09 | 湖北均瑶大健康饮品股份有限公司 | Bifidobacterium lactis strain J605 and application thereof |
-
2021
- 2021-09-18 CN CN202111101700.6A patent/CN113862181A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107893044A (en) * | 2017-12-27 | 2018-04-10 | 江南大学 | One plant of bifidobacterium longum and its application |
| CN110959676A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Fermented milk product containing bifidobacterium lactis and application thereof |
| CN110964655A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Bifidobacterium lactis BL-99 capable of regulating gastrointestinal flora and application thereof |
| CN110964657A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Bifidobacterium lactis BL-99 capable of improving immunity and application thereof |
| CN110577919A (en) * | 2019-10-14 | 2019-12-17 | 汉臣氏（沈阳）儿童制品有限公司 | heat-resistant bifidobacterium animalis subsp lactis separated from infant feces |
| CN112175864A (en) * | 2020-09-18 | 2021-01-05 | 山东得益乳业股份有限公司 | Bifidobacterium animalis and breeding method and application thereof |
| CN113088465A (en) * | 2021-04-02 | 2021-07-09 | 湖北均瑶大健康饮品股份有限公司 | Bifidobacterium lactis strain J605 and application thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115747121A (en) * | 2022-12-12 | 2023-03-07 | 威凯海思(山东)生物工程有限公司 | Bifidobacterium lactis HSLA-009, microbial inoculum and preparation method and application thereof |
| CN116445356A (en) * | 2023-04-28 | 2023-07-18 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof |
| CN116445356B (en) * | 2023-04-28 | 2024-01-30 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112175864B (en) | Bifidobacterium animalis and breeding method and application thereof | |
| CN111484957B (en) | Bifidobacterium animalis subsp lactis i797, and separation and purification method and application thereof | |
| CN103981118B (en) | A kind of bacillus subtilis feed addictive and its preparation method and application | |
| KR0123456B1 (en) | Probiotic germ | |
| Chuayana et al. | Antimicrobial activity of probiotics from milk products | |
| JP2007518693A (en) | Stable liquid probiotic composition, its preparation and application | |
| CN102191192A (en) | Animal Bifidobacterium and use method thereof | |
| CN104498383B (en) | A kind of lactobacillus fermenti Lactobacillus fermentum strain suo and application thereof of adjustable intestinal movement, Constipation | |
| CN106754470A (en) | The Lactobacillus rhamnosus in one plant of lacto source and its application | |
| CN106578064B (en) | Donkey-hide gelatin and lactic acid bacteria beverage and preparation method thereof | |
| CN114480229A (en) | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof | |
| CN110373368B (en) | Bifidobacterium longum strain ZJ1 and application thereof | |
| CN113862181A (en) | Bifidobacterium lactis RK-7782 with intestinal tract regulating function and application thereof | |
| CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
| CN104430847A (en) | Lactobacillus fermentum Lee working leavening agent product and constipation-prevention and health application thereof | |
| CN114806978B (en) | Lactobacillus johnsonii SXDT-23 and application thereof | |
| CN110893193A (en) | Novel application of bifidobacterium lactis BL-99 | |
| CN115354002A (en) | Bacillus coagulans BC07, application thereof, bacteriostatic agent, medicine, food and bacteriostatic method | |
| CN104381440A (en) | Lactobacillus fermentum Lee working fermenting agent product and application thereof to prevent constipation and keep healthy | |
| CN100482104C (en) | Process for preparing lactic acid bacteria oral liquor | |
| CN114990030B (en) | Lactobacillus acidophilus LA18 and application thereof in preparing product for regulating intestinal flora or immunoregulation | |
| CN111635875A (en) | Bifidobacterium longum CZ70 and method for preparing live bacterial blackberry fruit pulp by using same | |
| CN118006506A (en) | Lactobacillus reuteri as canine source, microbial inoculum and application thereof | |
| CN116286458B (en) | Lactobacillus plantarum LZ010 capable of reducing blood pressure and blood fat and application thereof | |
| CN1305383C (en) | Active bifidobacteria contained milk powder and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |